ESR1 and cancer: Our data indicates that the ERαY537S and ERαD538G mutations are sufficient to convert an ERα positive cancer cell, exhibiting E2-dependent proliferation and growth inhibition by antiestrogens, to one exhibiting E2-independent proliferation and resistance to high concentrations of OHT and ICI.